Rollout and Eligibility
The in England begins a mass rollout of , also known as tirzepatide, allowing GPs to prescribe it for weight loss to severely obese individuals with other health complications.
Eligibility in the first year targets individuals with a BMI over 40 and at least four obesity-related health issues, aiming to reach 220,000 people over three years.
Concerns and Criticisms
GPs express concerns about increased workload and the need for training, while pharmacy experts warn of potential supply pressures.
Critics emphasize the need for a balanced approach, warning against viewing weight-loss drugs as a sole solution and highlighting the importance of prevention and alternative weight loss services.